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The membrane dipeptidyl peptidase fibroblast 
activation protein- (FAP) was originally iden-
tified by the F19 monoclonal antibody derived 
from a mouse immunized with human lung fi-
broblasts. Using this antibody, it was originally 
reported that FAP was expressed by human as-
trocytomas (Rettig et al., 1986), but a second 
study refined this analysis and showed expres-
sion to be mainly by reactive fibroblasts in the 
tumor stroma of human adenocarcinomas and 
in healing dermal scars (Garin-Chesa et al., 1990). 
Since then, FAP+ stromal cells have been found 
also in chronic inflammatory lesions, such as pri-
mary biliary cirrhosis (Levy et al., 1999), athero-
sclerosis (Brokopp et al., 2011), and rheumatoid 
arthritis (Bauer et al., 2006). These observations 
suggest that the inflammatory, wound-healing 
aspect of the tumor microenvironment (Dvorak, 
1986) may account for the occurrence of FAP+ 
cells in the tumor stroma.
The presence of FAP+ stromal cells in tumors 
has stimulated three general lines of research re-
lated to tumor therapy. The first focuses on the 
enzymatic role of FAP itself rather than on the cell 
that expresses it. The evolutionary conservation 
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Fibroblast activation protein- (FAP) identifies stromal cells of mesenchymal origin in 
human cancers and chronic inflammatory lesions. In mouse models of cancer, they have 
been shown to be immune suppressive, but studies of their occurrence and function in 
normal tissues have been limited. With a transgenic mouse line permitting the biolumines-
cent imaging of FAP+ cells, we find that they reside in most tissues of the adult mouse. 
FAP+ cells from three sites, skeletal muscle, adipose tissue, and pancreas, have highly 
similar transcriptomes, suggesting a shared lineage. FAP+ cells of skeletal muscle are the 
major local source of follistatin, and in bone marrow they express Cxcl12 and KitL. Experi-
mental ablation of these cells causes loss of muscle mass and a reduction of B-lymphopoiesis 
and erythropoiesis, revealing their essential functions in maintaining normal muscle mass 
and hematopoiesis, respectively. Remarkably, these cells are altered at these sites in trans-
plantable and spontaneous mouse models of cancer-induced cachexia and anemia. Thus, 
the FAP+ stromal cell may have roles in two adverse consequences of cancer: their acquisi-
tion by tumors may cause failure of immunosurveillance, and their alteration in normal 
tissues contributes to the paraneoplastic syndromes of cachexia and anemia.
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the Fap gene that had been modified by inserting at the start 
codon a cassette comprised of the coding sequences of firefly 
luciferase, the human diphtheria toxin (DTX) receptor (DTR), 
and mCherry that were linked by E2A sequences (Fig. 1 A; 
Szymczak et al., 2004). BAC transgenic mice were injected with 
D-luciferin and assessed for bioluminescence before and after 
DTX treatment for 3 d. The entire dorsal and ventral surfaces of 
the BAC transgenic mice were bioluminescent. Treatment with 
DTX to deplete the FAP+ stromal cells diminished the biolumi-
nescent signal (Fig. 1 B). With the exception of lung, liver, and 
spleen, bioluminescence was observed in all organs that were ex-
amined in the BAC transgenic mouse and was sensitive to DTX 
treatment (Fig. 1 C and not depicted). FAP mRNA was also de-
tected in these tissues (Fig. 1 D) at levels that correlated with 
those of luciferase, a marker of the expression of the BAC trans-
gene (Fig. 1 E). FAP+ stromal cells were also identified by flow 
cytometric analysis of cells in enzyme-dispersed preparations of 
five of these tissues and organs (Fig. 1 F). These FAP+ stromal 
cells were sort purified, and mRNA for both FAP and lucif-
erase were selectively found in the sorted FAP+ cells, indicating 
that the transgene accurately reports transcription of endoge-
nous Fap (Fig. 1 G). FAP+ cells in transgenic mice also selectively 
showed a significantly increased mCherry mean fluorescence 
intensity compared with these cells in littermate controls, but 
the level was too low to be useful in detecting FAP expression.
FAP+ stromal cells may comprise a distinct cell lineage
FAP+ stromal cells from two mesenchymal tissues, visceral adi-
pose tissue and skeletal muscle, and an epithelial organ, the pan-
creas, were selected for further analysis. FAP+ cells from these 
sources were analyzed by flow cytometry and found to uni-
formly express CD90, CD140a, and Sca-1 (Fig. 2 A). To further 
investigate whether these represented homogenous popula-
tions, these FAP+ cells and FAP MEFs were sort purified 
and their transcriptomes were assessed by RNA-Seq. The 
high quality of the RNA-Seq data was confirmed by mapping 
statistics and by high correlations between biological repli-
cates (Table S1). To assess homogeneity of gene expression, 
expression levels were log transformed for both these cells and 
publically available data for CD4+ T-helper subsets (Wei et al., 
2011). The degree to which this transformation conforms to 
a model bimodal distribution is a measure of the homogene-
ity of a cellular population. Genes below the cut off to be in-
cluded in the highly expressed peak but above the cut off to 
be included in the lowly expressed peak were classified as inter-
mediate genes (Hebenstreit et al., 2012). The percent of inter-
mediate (%int) genes is a read out of conformity to the bimodal 
model, with lower numbers indicating greater homogeneity 
(Fig. 2 B; Hebenstreit et al., 2011). The %int values indicated 
that the FAP+ cells from these four organs and tissues were at 
least as homogeneous as were the four subsets of CD4+ T cells.
The similarity of the transcriptomes of the FAP+ cells was 
assessed by performing expression correlation, principal com-
ponent analysis (PCA), clustering, and differential expression 
analyses. The transcriptomes of the FAP+ cells from the three 
tissues were highly correlated with each other and were distinct 
of FAP has led to a suggestion that it may have important 
functions (Park et al., 1999). FAP/ mice, however, have no 
striking phenotypes (Niedermeyer et al., 2000), inhibiting the 
dipeptidyl peptidase activity of FAP has only a modest effect 
on tumor growth in the mouse (Santos et al., 2009), and FAP 
inhibitors have not demonstrated clinical efficacy in humans 
(Eager et al., 2009a,b). The second line of research concerns 
the finding of selective uptake of an 131I-labeled, humanized 
form of the F19 antibody (sibrotuzumab) by tumors and not 
by normal tissues in patients with colorectal carcinoma or non-
small cell lung cancer (Scott et al., 2003). This apparently 
restricted distribution of FAP+ cells suggested that cancer ther-
apeutics can be localized to the tumor site by the use of either 
anti-FAP antibody conjugates (Hofheinz et al., 2003; Scott 
et al., 2003) or the enzymatic activity of FAP itself (Aertgeerts 
et al., 2005; LeBeau et al., 2009; Huang et al., 2011). The third 
line of research has been prompted by the recent observation 
that conditionally depleting FAP+ stromal cells from immuno-
genic, transplanted tumors in mice led to immune control of 
tumor growth (Kraman et al., 2010) and so is based on a bio-
logical role of the tumoral FAP+ stromal cell rather than on 
the FAP protein. Accordingly, the FAP+ stromal cell may be 
both a means by which cytotoxic drugs can be delivered to 
tumors for the purpose of killing cancer cells and a cytotoxic 
target itself for the purpose of alleviating tumoral immune 
suppression and promoting cancer immunosurveillance.
A contraindication to any potential cancer therapy that may 
indiscriminately deplete FAP+ cells, however, might be their 
presence in normal tissues. This consideration is raised by the 
finding of FAP+ stromal cells in two normal tissues of humans, 
the placenta and uterus (Dolznig et al., 2005), in the bone 
marrow of the adult mouse (Kraman et al., 2010), and in the 
somites of the mouse embryo (Niedermeyer et al., 2001). The 
full significance of this potential contraindication to the sys-
temic depletion of FAP+ cells is not known, however, because 
there has not been a comprehensive analysis of occurrence and 
function of FAP+ stromal cells in normal tissues and organs.
We generated a transgenic mouse model that permits both 
the bioluminescent imaging of cells expressing FAP and their 
conditional ablation. The use of this model has demonstrated 
that FAP+ cells reside in almost all tissues of the adult mouse. In 
at least three of these, they share a common transcriptome, and 
in at least two, skeletal muscle and bone marrow, they have the 
essential functions of maintaining skeletal muscle mass and nor-
mal hematopoiesis, respectively. Remarkably, FAP+ stromal cells 
are altered in skeletal muscle and bone marrow in two mouse 
models of cancer-induced cachexia and anemia, two cancer co-
morbidities which severely reduce quality of life and contribute 
to fatal outcome. Therefore, FAP+ cells of normal tissues medi-
ate essential physiological functions, and their alteration in can-
cer may contribute to two paraneoplastic syndromes.
RESULTS
FAP+ stromal cells are widely distributed in the adult mouse
A transgenic albino (Tyr/) C57BL/6 mouse line was estab-
lished with a bacterial artificial chromosome (BAC) containing 
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correlations and on both reads per kilobase million (RPKM) 
and bias-adjusted fragments per kilobase million (FPKM) 
values (not depicted). PCA demonstrated that FAP+ stromal 
cells from these sites formed a discrete cluster that was distinct 
from that of the CD4+ T cells and from the FAP MEFs 
from that of FAP MEFs (Fig. 2 C). Previously published 
RNA-Seq data on CD4+ T cell subsets, which were used as 
the outgroup (Wei et al., 2011), showed these cells also to be 
distinct from FAP+ cells and FAP MEFs (Fig. 2 C). These 
relationships were observed using both Pearson and Spearman 
Figure 1. The tissue distribution of FAP+ stromal cells in the adult mouse. (A) A Fap-containing BAC was modified by inserting at the start 
codon a cassette encoding the DTR, Luc2, and mCherry linked by E2A sequences. (B) BAC transgenic mice in which luciferase and the DTR are ex-
pressed in FAP+ stromal cells and littermate mice were assayed for bioluminescence before and 24 h after two daily doses of 25 ng/g DTX. (C) Organs 
that had been dissected from DTX- or vehicle-treated BAC transgenic mice from B were assessed for bioluminescence. (B and C) The scale represents 
relative counts. (D) FAP mRNA levels were measured in different tissues by qRT-PCR. (E) FAP mRNA levels were correlated with those of luciferase,  
a marker of the expression of the BAC transgene, across different tissues by qRT-PCR. (F) Tissues were enzymatically dissociated, and cells were 
stained with antibodies to FAP and CD45 for analysis by flow cytometry. Numbers represent the percentage of live cells gated as FAP+. (G) CD45FAP+, 
CD45FAP, and CD45+ cells were sort purified from skeletal muscle and assessed by qRT-PCR for FAP and luciferase/transgene mRNA. Error bars 
represent SEM. MOE, main olfactory epithelium. Data are representative of more than three independent analyses (n ≥ 3; B–G).
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Figure 2. Analysis of the transcriptomes of FAP+ cells from adipose tissue, skeletal muscle, and pancreas. (A) FAP+ cells were assessed 
by flow cytometry for their expression of the membrane proteins CD90 (Thy1), CD140a (PDGFR), and Sca-1 (Ly6A/E), which are characteristic of 
certain mesenchymal cells. Filled histograms represent isotype staining, and the black lines denote the specific stains. (B) The RNA-Seq data for 
each of the cell types were log transformed and modeled as bimodal distributions. The %int represents the degree of heterogeneity within each 
population. The density value is indicated in blue. The yellow line represents the bimodal fit for the lowly expressed transcripts and the purple line 
for the highly expressed transcripts, and the red line indicates the overall density value. (C) The Pearson’s r2 and Spearman’s  correlations were 
calculated for the RPKM gene expression levels of FAP+ cells, FAP MEFs, and CD4+ T cell subsets after removal of low expressed/nonexpressed 
genes. (D) PCA analysis of VST (counts) of FAP+ cells, CD4+ T cell subsets, and MEFs is shown. (E) VST clustering of RPKM levels of replicate samples 
of FAP+ cells, CD4+ T cell subsets, and MEFs is shown. (F) The percentage of differentially expressed genes among the different cells was deter-
mined by DESeq and edgeR using count data. The highlighted cells here and in C show the correspondence between high levels of similarity in 
these two analyses of gene expression. Th1, Th2, and iTreg refer to the CD4+ T cell subsets. VA, SkM, and Pan refer to FAP+ cells from visceral adi-
pose tissue, skeletal muscle, and pancreas, respectively. See also Table S1.
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FAP MEFs and the CD4+ T cell subsets (Fig. 2 F). This was 
observed whether considering counts or fragments using both 
DESeq and edgeR (not depicted). From these various analy-
ses, it can be concluded that the FAP+ stromal cells from adipose 
tissue, skeletal muscle, and pancreas consistently appear to be as 
similar to each other as are members of the CD4+ T cell lineage, 
supporting the possibility that they may be members of a devel-
opmentally distinct cell lineage.
Depleting FAP+ stromal cells from skeletal muscle causes  
an atrophic muscle response
In this first examination of the biological consequences of the 
loss of FAP+ stromal cells, we limited our analysis to obvious 
(Fig. 2 D). These groupings were observed with PCA when 
variance-stabilized transform (VST) counts or VST fragments 
(not depicted) were used. Cluster analysis confirmed the similar-
ity of the FAP+ stromal cells from the three tissues and suggested 
that, as anticipated, they were more related to FAP MEFs than 
to the subsets of CD4+ T cells (Fig. 2 E). This same pattern of 
clustering was seen using both VST counts and fragments and 
using hierarchical clustering with different distance metrics on 
RPKM data for the whole transcriptome or just transcription 
factors (not depicted). Finally, differential gene expression analy-
sis showed that few genes were differentially expressed when 
the FAP+ cells from the three tissues were compared, whereas 
there were many more differentially expressed genes relative to 
Figure 3. Depletion of FAP+ stromal cells 
and loss of skeletal muscle mass. (A) BAC 
transgenic mice and littermates were treated 
with DTX for 2 d, and total body weight and 
food intake were measured each day during 
the ensuing 3 wk. Arrows indicate when DTX 
was given, and the red highlighting shows the 
period over which it was being administered. 
(B) The mass of the quadriceps muscles from 
BAC transgenic mice and littermates was 
measured on days 3 and 22 after DTX treat-
ment. (C) The mean cross-sectional area of 
the fibers of the quadriceps muscles from BAC 
transgenic mice and littermates taken 22 d 
after DTX treatment was measured, after fi-
bers were delineated by staining with anti-
body to the basal lamina. Bar, 100 µm. (D) The 
number of FAP+ cells and the level of FAP 
mRNA in quadriceps muscles of BAC trans-
genic mice as a percentage of littermates 
were measured 3 and 22 d after DTX treat-
ment. (E) The mRNA levels for atrogin-1, 
MuRF1, Fst, Lama2, and Mstn in quadriceps 
muscles of BAC transgenic mice and litter-
mates were measured 3 and 22 d after DTX 
treatment. (F) The levels of Fst protein in 
quadriceps muscles of BAC transgenic mice 
and littermates were measured by immuno-
blot analysis 10 d after DTX treatment.  
(G) Quadriceps muscle from a normal mouse 
was stained with antibodies to FAP and lam-
inin and assessed by confocal microscopy. 
(H) The FAP+ subset of enzymatically dissoci-
ated cells from quadriceps muscle were sort 
purified, and the mRNA levels of Lama2, 
Fst288, and Fst315 in FAP+ cells were deter-
mined by RNA-Seq. (I) The indicated subsets of 
enzymatically dissociated cells from quadriceps 
muscle were sort purified, and the mRNA levels 
of Fst, Lama2, Mstn, and FAP were deter-
mined by qRT-PCR. Error bars represent  
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Data are representative of more than three inde-
pendent analyses (n ≥ 3; A) or are representative 
of two independent analyses (n ≥ 5; B–F).
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Figure 4. FAP+ cells of the bone marrow and hematopoiesis. (A) The cellularity of the femoral bone marrow from BAC transgenic mice and lit-
termates was determined by hematoxylin and eosin staining after 3-d treatment with DTX. (B) Individual populations of hematopoietic cells from the 
femoral bone marrow of BAC transgenic mice and littermates were analyzed by flow cytometry after 3-d treatment of the mice with DTX. (C) 7 d after 
DTX administration, samples of peripheral blood from transgenic and littermate mice were assayed for hemoglobin, erythrocyte numbers, mean cor-
puscular hemoglobin, and mean corpuscular volume. (D) The proportions of FAP+ cells in enzyme-dissociated bone and bone marrow preparations 
from BAC transgenic mice and littermates were assessed by flow cytometry after 3-d treatment of the mice with DTX. (E) The mRNA levels of Cxcl12 
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(Mstn) and activin A, and follistatin (Fst), an inhibitor of their 
binding to the AcvRIIB (McPherron and Lee, 1997; Lee and 
McPherron, 2001; Zimmers et al., 2002). The AcvRIIB sig-
nals Foxo-dependent expression of the myocyte-specific E3 
ubiquitin ligases, muscle atrophy F-box/atrogin-1, and mus-
cle RING finger protein/MuRF1 (Bodine et al., 2001; Gomes 
et al., 2001; Glass, 2010), which ubiquitinate muscle-specific 
proteins and promote their proteasomal degradation (Bodine 
et al., 2001; Gomes et al., 2001; Lee et al., 2005; McFarlane 
et al., 2006). Muscle wasting may also be caused by abnormali-
ties of the -dystroglycan complex and laminin 2 (Lama2) 
of the basal lamina, which induce the expression of atrogin-1 
and MuRF1 (Carmignac et al., 2011).
The depletion of FAP+ stromal cells affects both pathways 
of muscle atrophy by causing an acute and persistent decrease 
of Fst and Lama2 mRNA levels at days 3 and 22. These 
changes led to a transient increase in atrogin-1 and MuRF1 
mRNA levels at day 3, which did not persist at day 22, 
perhaps because of a compensatory decrease of the Mstn 
mRNA level (Fig. 3 E). Fst protein in the quadriceps mus-
cle also was decreased, confirming the finding of the reduced 
Fst mRNA levels (Fig. 3 F). Similar changes were seen in 
the gastrocnemius muscle that persisted at least until day 90 
after DTX (not depicted).
We examined the skeletal muscle FAP+ stromal cell to de-
termine whether its depletion was directly responsible for these 
changes. Confocal microscopy showed these cells to be located 
outside the basal lamina of the myofibers, distinguishing them 
from satellite cells that reside inside the basal lamina (Fig. 3 G; 
Mauro, 1961). RNA-Seq analysis of the sort-purified FAP+ 
stromal cells demonstrated transcription of the genes encoding 
Lama2 and both the Fst288 and Fst315 isoforms (Fig. 3 H). 
Analysis by quantitative RT-PCR (qRT-PCR) of mRNA 
from sorted skeletal muscle cells revealed that FAP+ stromal 
cells were the major source of both Fst and Lama2 and that 
FAP/CD45 cells, presumably mainly myocytes, were the 
source of Mstn (Fig. 3 I). FAP expression was limited to the 
FAP+ population and CD3 to the CD45+ cells, confirming 
the sort purity (Fig. 3 I). Therefore, the depletion of skeletal 
muscle FAP+ stromal cells was directly responsible for the loss 
of Fst and Lama2 in this tissue, which may reasonably be 
considered to be the basis of the acute increase of atrogin-1 
and MuRF1 (Gomes et al., 2001). DTX-induced weight loss 
in the BAC transgenic mice was not associated with an 
increase in the plasma levels of corticosterone, IL-6, or TNF 
(not depicted), all of which have been reported to cause loss of 
muscle mass. We do not have an explanation for the transient 
changes occurring soon after DTX administration. Although 
mice depleted of FAP+ cells did not exhibit any reduction 
in activity or other signs of distress, there were two conspicu-
ous changes affecting fundamental physiological processes: 
rapid weight loss (Fig. 3 A) and altered hematopoiesis, as mani-
fested by hypocellularity of the bone marrow (Fig. 4 A). The 
former was accompanied initially by decreased food intake, 
but normal food intake resumed by 10 d after DTX without 
a corresponding recovery in weight, excluding the transient 
alteration in food intake as an explanation for the persistent 
loss of total body weight (Kennedy, 1950). There was a sig-
nificant reduction in muscle mass as seen by direct measure-
ment of the quadriceps taken 7 and 22 d after DTX treatment, 
and measurement of a myofiber cross-sectional area 22 d 
after DTX revealed a significant decrease (Fig. 3, B and C), 
indicating atrophy rather than loss of myocytes. Therefore, de-
pletion of FAP+ stromal cells causes cachexia, which is a re-
duction in muscle mass despite adequate food intake (Evans 
et al., 2008).
Serum was taken on day 12 after DTX and assessed for 
changes that would reflect a basic metabolic change that could 
explain the persistent weight loss (Table 1). Compared with 
the littermate controls, DTX-treated mice had a tendency to-
ward elevated serum alanine aminotransferase levels. Because 
there were no other abnormal liver function tests, this finding 
is likely to reflect the skeletal muscle catabolism that was oc-
curring in these mice. Serum insulin and glucose levels were 
normal, excluding a pancreatic endocrine dysfunction. Renal 
insufficiency was ruled out with the normal urea nitrogen 
levels, and albumin and total protein concentrations were 
also normal. Finally, fecal energy, as determined by bomb cal-
orimetry, was the same in DTX-treated and littermate con-
trols, which indicated that weight loss was not caused by 
intestinal malabsorption.
Having excluded a generalized metabolic disorder result-
ing from the depletion of FAP+ cells as the basis for the DTX-
induced cachexia, an abnormality caused by the loss of FAP+ 
stromal cells from skeletal muscle itself (Fig. 1 C) that directly 
affected this tissue was sought. The loss of skeletal muscle mass 
(Fig. 3 B) was associated with a decrease in the mean cross-
sectional area of the myofibers (Fig. 3 C). A persistent loss of 
FAP+ cells caused by DTX treatment was confirmed by mea-
surement of FAP mRNA and of the number of FAP+ cells in 
the quadriceps (Fig. 3 D). Muscle wasting in the mouse may 
be secondary to increased signaling through the type II activin 
receptor (AcvRIIB), which may be caused by an imbalance 
between the levels of the TGF- family members, myostatin 
and KitL in cells of the femoral bone marrow from BAC transgenic mice and littermates were measured by qRT-PCR after 3-d treatment of the mice 
with DTX. (F) The protein levels of Cxcl12 and KitL in lysates of bone marrow from BAC transgenic mice and littermates were measured by ELISA after 
3-d treatment of the mice with DTX. (G) A cross-section of normal mouse femur was stained with antibodies to FAP, osteopontin, and osteocalcin and 
assessed by confocal microscopy. (H) Subsets of enzymatically dispersed cells from femoral bone and marrow were FACS purified, and the sorted pop-
ulations were assessed by qRT-PCR for expression of FAP, Cxcl12, KitL, osteopontin, osteocalcin, and Lepr. Error bars represent SEM. *, P < 0.05; **, P < 0.01; 
***, P < 0.001. Data are representative of at least two independent analyses (n ≥ 4; A, B, D, and E) or one confirmatory analysis (n = 6; F). Combined 
data are from three independent experiments (n ≥ 4; B).
 
1144 FAP+ stromal cells in cachexia and anemia | Roberts et al.
FACS sorted from pooled bone marrow cells of six donors, 
but not those from bone, expressed Cxcl12 and KitL (Fig. 4 H). 
In keeping with the confocal microscopy, only FAP+ cells iso-
lated from bone expressed osteocalcin (Fig. 4 H). The finding 
that the bone marrow–derived FAP+ stromal cell expresses 
Cxcl12 and KitL and has an essential role in erythropoiesis and 
B lymphopoiesis is consistent with at least some of this popu-
lation being comprised of the CAR (Cxcl12-abundant retic-
ular) cell (Omatsu et al., 2010). The additional finding that the 
FAP+ cells from the bone marrow expressed the leptin recep-
tor (Lepr; Fig. 4 H) identifies them as a component of the HSC 
niche (Ding et al., 2012). Endothelial cells may have not been 
present in the FACS-sorted FAP/CD45 cells from the bone 
marrow, thus accounting for the absence of detectable mRNA 
for KitL and Lepr in this population.
Cancer-induced cachexia and anemia and alteration  
of FAP+ stromal cells in skeletal muscle and bone marrow
Patients with cancer suffer not only from direct consequences 
of tumors, but also from indirect, paraneoplastic effects, two 
of which are cachexia and anemia. It has been difficult to un-
derstand how cancers alter the function of two such disparate 
organ systems as skeletal muscle and the bone marrow because 
they had not been known to share a biologically relevant cell 
type. The present finding of the essential roles of the FAP+ 
stromal cell in skeletal muscle metabolism and erythropoiesis 
made it a candidate for the shared entity that may be affected 
by cancer to cause cachexia and anemia.
To examine the possibility that alterations of the FAP+ 
stromal cell may contribute to cancer cachexia and anemia, 
C26 colon carcinoma cells were implanted subcutaneously 
in BAC transgenic C57BL/6 × BALB/c F1 mice (Tanaka 
et al., 1990). Within 3–4 wk, the mice suddenly lost weight, 
despite their food intake being comparable with nontumor-
bearing littermates (Fig. 5 A), and the level of whole body, 
FAP-dependent bioluminescence became diminished at the 
time that the mice began to lose weight (Fig. 5 B). The dissected 
reduction in food intake, as an analysis of hypothalamic tissue 
(Coll et al., 2007) revealed increased expression of the orexi-
genic peptides NPY and AgRP in DTX-treated BAC trans-
genic mice (not depicted).
Depleting FAP+ cells from the bone marrow suppresses 
erythropoiesis and B lymphopoiesis
The acute hypocellularity of the bone marrow (Fig. 4 A) seen 
3 d after DTX treatment of BAC transgenic mice reflected 
a marked decrease in the subpopulations of megakaryocyte-
erythroid progenitors (MEPs: Lin, c-Kit+,Sca-1, CD16/32, 
CD34), proerythroblasts (pro-Es: c-Kit+, CD71+, Ter119int), 
and pro–B cells (pro–Bs: CD19+, IgM, c-Kit+) and modest 
losses of the common lymphoid progenitors (CLPs: Lin, 
CD135+, CD127+) and granulocyte-macrophage progenitors 
(Lin, c-Kit+, Sca-1, CD16/32+, CD34+; Fig. 4 B). The mul-
tipotent progenitors (Lin, c-Kit+, Sca-1+, CD135+) were 
slightly enriched, and there was no change in the hematopoi-
etic stem cells (HSCs: Lin, c-Kit+, Sca-1+, CD150+, CD48, 
CD34; Omatsu et al., 2010). Peripheral blood taken 7 d 
after DTX treatment showed that these mice had a normo-
cytic, normochromic anemia with reduced erythrocyte num-
ber and hemoglobin but normal mean corpuscular volume 
and hemoglobin (Fig. 4 C). The decreased femoral biolumi-
nescence (Fig. 1 C) in the DTX-treated mouse was caused by 
loss of FAP+ stromal cells from both bone and bone marrow 
(Fig. 4 D). This loss was associated with decreased expression 
of two contributors to hematopoiesis, Cxcl12 and KitL, at both 
the transcript and protein levels (Fig. 4, E and F).
Confocal microscopy of bone revealed the presence of 
two types of FAP+ cells: those showing triple staining for FAP, 
osteocalcin, and osteopontin, which have a characteristic cu-
boidal aspect and line the bone endosteum, and those that are 
deeper in the marrow and are positive for osteopontin but not 
osteocalcin (Fig. 4 G). These anatomically distinct FAP+ stro-
mal cells also differed with respect to their potential roles in 
the hematopoietic phenotype in that FAP+ cells that had been 
Table 1. Analyses of plasma and feces from transgenic and littermate mice 12 d after DTX administration
Parameter Littermates Transgenics P-value Normal range
Gamma glutamyl peptidase (U/liter) 0.2 ± 0.2 0.0 ± 0.0 0.35 0.0–0.2
Aspartate aminotransferase (U/liter) 150.0 ± 45.1 167.2 ± 28.2 0.75 59–247
Alanine aminotransferase (U/liter) 24.4 ± 3.1 114.6 ± 51.3 0.12 28–132
Urea nitrogen (mmol/liter) 7.2 ± 0.5 6.1 ± 0.6 0.79 6.4–10.4
Glucose (mmol/liter) 15.0 ± 0.2 14.1 ± 0.8 0.38 9.0–19.3
Insulin (µg/liter) 0.3 ± 0.1 0.3 ± 0.1 0.61 0.1–2.9
Albumin (g/liter) 27.6 ± 2.0 26.6 ± 1.2 0.68 25–48
Bilirubin (µmol/liter) 6.4 ± 0.9 6.0 ± 1.0 0.78 2–15
Total protein (g/liter) 51.0 ± 2.3 52.2 ± 0.6 0.62 36–66
Phosphate (mmol/liter) 2.1 ± 0.1 2.6 ± 0.2 0.10 1.97–3.26
Calcium (mmol/liter) 2.0 ± 0.1 1.9 ± 0.1 0.26 1.47–2.35
Fecal energy (kJ/g) 13.7 ± 0.7 13.7 ± 0.5 0.98
Data are representative of two independent analyses and are expressed as mean ± SEM (n ≥ 5). Fecal energy does not have a well-established normal range as it differs 
depending on chow so much. As a result, we have simply compared with littermate controls as these were fed at the same time with the same chow.
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The femoral marrow of C26-bearing mice also showed a 
significant loss of FAP+ cells (Fig. 6 D), confirming the bio-
luminescence findings (Fig. 5 C). FACS analysis of the bone 
marrow cells revealed depletion of the MEP, pro-E, pro–B, 
and CLP populations (Fig. 6 D), mirroring the effects of 
DTX-mediated depletion of the FAP+ cell (Fig. 4 B). This 
loss of FAP+ cells was associated with a decrease in expression 
of both Cxcl12 and KitL from the bone marrow (Fig. 6 E).
Cachexia frequently develops in patients with pancreatic 
ductal adenocarcinoma (PDA; Tisdale, 2009). A genetically 
engineered mouse model of this disease, the KPC (KrasG12D/+; 
Tp53R172H/+;Pdx-1 Cre) mouse in which the Cre-induced 
expression of the oncogenic KrasG12D and Trp53R172H alleles 
is directed specifically to pancreatic progenitor cells, has been 
shown to recapitulate the major histopathological, genomic, 
and clinical characteristics of human PDA (Hingorani et al., 
2005). This autochthonous cancer model offered an opportunity 
to determine whether in these mice that became cachectic, 
which comprised 52% of terminal tumor bearing animals, 
there were similar abnormalities of FAP+ stromal cells. In PDA-
bearing KPC mice that appeared on gross inspection to be 
tumors (2.5 ± 0.1 g, mean ± SEM) were bioluminescent 
(Fig. 5 C), indicating an accumulation of FAP+ stromal cells 
at this site, which contrasted with the diminished biolumi-
nescence of six of the dissected tissues: femur, pancreas, sali-
vary gland, skin, and the quadriceps and gastrocnemius muscles 
(Fig. 5 C). The small intestine also appeared to have dimin-
ished bioluminescence, whereas the stomach and colon had 
increased bioluminescent signals.
The reduction in quadriceps muscle mass (Fig. 6 A) con-
firmed the occurrence of cachexia. The diminished biolumi-
nescence of this tissue was caused by decreased expression of 
the endogenous Fap gene, which, importantly, was associated 
with a reduction in two products of the FAP+ stromal cell, Fst, 
measured both as mRNA and protein, and Lama2 (Fig. 6, B 
and C). These changes were accompanied by elevated expres-
sion of atrogin-1 and MuRF1, presumably reflecting increased 
signaling through the AcvRIIB secondary to the decreased 
Fst and Lama2, and by a twofold increase in skeletal muscle 
Mstn (Fig. 6 B), which occurs with cachexia in this tumor 
model (Zhou et al., 2010). The same findings were observed 
in the gastrocnemius (not depicted).
Figure 5. The transplanted C26 carcinoma, cachexia, and systemic alterations in FAP+ stromal cells. (A) Whole body weight and food intake 
of C57BL/6 × BALB/c F1 mice with and without ectopic C26 tumors were measured during the 3–4-wk post-tumor implantation period. (B) C26 cells 
were subcutaneously inoculated into BAC transgenic C57BL/6 × BALB/c F1 mice. Whole body bioluminescence was quantified for the entire dorsal 
surface of the mice at the indicated times. (C) The levels of bioluminescence of the excised C26 tumor and several tissues of tumor-bearing mice and 
littermate controls were assessed. (B and C) Scale represents relative counts. Error bars represent SEM. Data are representative of three independent 
analyses (n = 4 for A and B; representative n = 1 for C).
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with PDA-bearing noncachectic KPC mice and nontumor-
bearing littermate mice. This was accompanied by decreases 
in FAP, Fst, and Lama2 mRNA levels (Fig. 7 B). Mstn mRNA 
levels in the quadriceps muscle were not increased. All tumor-
bearing KPC mice, including noncachectic mice, also dis-
played a normocytic, normochromic anemia that is consistent 
with the type of anemia commonly observed in cancer pa-
tients (Fig. 7 C). In these PDA-bearing mice, there were sig-
nificant decreases in the relative number of FAP+ cells that 
could be recovered from the bone marrow, as well as in the rela-
tive numbers of MEPs, pro-Es, pro–Bs, and CLPs (Fig. 7 D). 
The reduction in FAP+ cells from the femur was accompa-
nied by a loss of both Cxcl12 and KitL (Fig. 7 E). Therefore, 
cachexia and anemia in the KPC model of PDA is associ-
ated with an abnormality of FAP+ stromal cells in skeletal 
muscle and bone marrow. We have not excluded the possi-
bility that cancer-induced abnormalities of FAP+ cells in other 
tissues may also cause physiological changes, as suggested by 
the systemic alteration in FAP-dependent bioluminescence 
in C26-bearing mice (Fig. 5, B and C) and by the finding of 
decreased levels of FAP mRNA in the heart and salivary 
gland of cachectic KPC mice (Fig. 7 F).
DISCUSSION
Before the present study, studies of FAP+ stromal cells had em-
phasized their occurrence in tumors and a range of chronic in-
flammatory conditions, with little attention being given to their 
presence in normal tissues (Rettig et al., 1986; Garin-Chesa 
et al., 1990; Levy et al., 1999; Bauer et al., 2006; Brokopp et al., 
2011). Therefore, we were surprised to find that FAP+ stro-
mal cells are present in the majority of normal tissues and 
organs, raising the possibility that FAP expression may iden-
tify a stromal cell lineage with biological roles that extend 
beyond those associated with wound healing (Fig. 1). Three 
experimental challenges were presented by this finding: de-
termining whether the expression of FAP is indicative of a 
stromal cell lineage, elucidating the functions of FAP+ stromal 
cells in normal tissues, and seeking abnormalities of these cells 
that may contribute to disease.
FAP+ cells from two mesenchymal organs, visceral adipose 
and skeletal muscle, and an epithelial organ, the pancreas, showed 
highly similar transcriptomic profiles. The degree to which 
these correlated was similar to that of the CD4+ T cell subsets, 
known members of a common lineage (Fig. 2 C). The FAP+ 
cells from these three sites also had very few differentially ex-
pressed genes (Fig. 2 F), and this similarity cannot be ascribed 
to their sharing a common fibroblast gene expression profile, 
which, for the purpose of this study, was defined by the FAP 
MEF transcriptome (Fig. 2, C and D). Fibroblasts have been 
shown to be diverse when isolated from different sites (Chang 
et al., 2002), whereas the FAP+ cells isolated from three differ-
ent tissues are very similar. Thus, FAP+ cells may represent a 
distinct subset of mesenchymal cells, but more definitive stud-
ies are required to establish this relationship.
The presence in the BAC luciferase transgene of the 
cassette encoding the DTR afforded an opportunity for a 
cachectic, examination of the quadriceps muscles revealed 
significant decreases in mass (Fig. 7 A) and increases in the 
mRNA levels of atrogin-1 and MuRF1 (Fig. 7 B) as compared 
Figure 6. Alterations of FAP+ cells in the quadriceps muscle and 
bone marrow of cachectic mice bearing C26 tumors. (A and B) The 
quadriceps muscles from cachectic, C26-bearing and nontumor-bearing 
littermates were assessed for mass (A) and the mRNA levels of atrogin-1, 
MuRF1, Mstn, FAP, Fst, and Lama2 (B). (C) The levels of Fst protein in ly-
sates of quadriceps muscles from cachectic, C26-bearing and nontumor-
bearing littermates were measured by immunoblot analysis. (D) Individual 
populations of hematopoietic cells from the femoral bone marrow of 
cachectic, C26-bearing and nontumor-bearing littermates were assessed 
by flow cytometry. (E) The levels of Cxcl12 and KitL protein in lysates of 
cells recovered from the femoral bone marrow of cachectic, C26-bearing 
and nontumor-bearing littermates were measured by ELISA. Error bars 
represent SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Combined data are 
from three independent analyses (n = 1–5).
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generalized stress resulted from their depletion. However, DTX-
treated BAC transgenic mice initially appeared free from signs 
of severe distress such as piloerection, hunching, and altered 
loss-of-function approach to the analysis of the roles of FAP+ 
stromal cells in normal tissues. Their wide distribution could 
have rendered this approach relatively uninformative if severe, 
Figure 7. Alterations of FAP+ cells in the quadriceps muscle and bone marrow of KPC mice with PDA. (A and B) The quadriceps muscles from 
PDA-bearing KPC mice with and without cachexia and littermates were assessed for mass (A) and the mRNA levels of atrogin-1 MuRF1, FAP, Fst, Lama2, 
and Mstn (B). (C) Peripheral blood from PDA-bearing mice and nontumor-bearing littermates was assayed for hemoglobin, erythrocyte number, mean 
corpuscular hemoglobin, and mean corpuscular volume. (D) Individual populations of hematopoietic cells from the femoral bone marrow of PDA-bearing 
mice and nontumor-bearing littermates were assessed by flow cytometry. (E) The levels of Cxcl12 and KitL protein in lysates of cells recovered from the 
femoral bone marrow of PDA-bearing KPC mice and nontumor-bearing littermates were measured by ELISA. (F) The mRNA levels of FAP in heart and 
salivary glands from KPC, PDA-bearing mice with and without cachexia and littermates were assessed by qRT-PCR. Error bars represent SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. Combined data are from three independent analyses (n = 1–5).
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also not be affected in this system, thus explaining the lack of 
an HSC phenotype. These other sources may comprise rare 
populations in the CD45FAP sorted population and so 
expression of Lepr, KitL, and Cxcl12 would not appear. How-
ever, as the whole bone marrow level of Cxcl12 and KitL was 
reduced upon FAP+ cell ablation (Fig. 4, E and F), it can be 
concluded that the FAP+ cells do constitute a major source 
of these factors.
The finding that depletion of FAP+ stromal cells led to loss 
of muscle mass and anemia predicted that disease-associated 
alterations in FAP+ cells could lead to similar phenotypes. 
Because both cachexia and anemia are common syndromes 
associated with cancer, there was the intriguing possibility that 
the cachexia and anemia caused by cancer may have a com-
mon etiological basis involving this cell. This possibility was 
supported by the finding of reduced FAP-dependent tissue 
bioluminescence of the cachectic mice bearing the C26 colon 
carcinoma (Fig. 5) and the fact that the C26-induced abnor-
mality of FAP+ cells in skeletal muscle and bone marrow was 
accompanied by a diminution of their tissue-specific func-
tions of producing Fst, Lama2, Cxcl12, and KitL, which could 
account for the occurrence of cachexia and anemia (Fig. 6). 
That these changes in the FAP+ cells were not an artifact of 
a transplantable tumor model was shown by finding a com-
parable abnormality of FAP+ stromal cells from the skeletal 
muscle and bone marrow of cachectic and anemic mice bear-
ing spontaneous PDA (Fig. 7). The DTX-mediated ablation 
of FAP+ cells demonstrates that these changes may be caus-
ative rather than correlative (Figs. 3 and 4) and indicates that 
these two experimental systems may share a common etiol-
ogy. The presence of anemia in noncachectic KPC animals 
and the loss of FAP+ cells in the bone marrow of these animals 
indicate that in this slower developing tumor model, there is a 
loss of FAP+ cells from the bone marrow before the skeletal 
muscle. Further work will be needed to elucidate the factors 
from the tumor which bring about these changes and how 
they may differentially affect bone marrow and skeletal mus-
cle FAP+ cells.
Many studies have focused on the cytokines TNF and 
IL-6 as mediating wasting syndromes associated with cancer 
(Tisdale, 2009). There is, however, an imperfect correlation 
between elevated cytokines and the occurrence of these pa-
thologies (Mantovani et al., 2000), and neutralizing these cyto-
kines has not suppressed their occurrence (Wiedenmann 
et al., 2008). Recent preclinical and clinical studies of cancer 
cachexia have shown alterations of the muscular dystrophy–
associated dystrophin glycoprotein complex (Acharyya et al., 
2005) and excessive signaling by the AcvRIIB of skeletal mus-
cle myocytes (Benny Klimek et al., 2010; Zhou et al., 2010). 
Moreover, Fst was found to be reduced in the muscle of cachec-
tic rats with a transplanted model of cancer cachexia (Costelli 
et al., 2008), further implicating the AcvRIIB pathway. This 
study extends these studies by finding a cellular basis of reduced 
Fst in skeletal muscle of tumor-bearing cachectic mice. Fur-
thermore, as the FAP+ cell also is the source of Lama2 in skele-
tal muscle, its alteration offers an explanation for the abnormality 
patterns of movement despite the conspicuous changes af-
fecting food intake, body weight, skeletal muscle mass, and 
hematopoiesis (Figs. 3 and 4). It has been shown previously 
that muscle atrophy caused by a range of metabolic challenges 
is mediated by the actions of atrogin-1 and MuRF1 (Sandri 
et al., 2004). One pathway leading to the expression of these 
E3 ligases is AcvRIIB signaling in response to certain TGF- 
family members (Zhou et al., 2010). Accordingly, either in-
creased levels of Mstn or activin A or reduced levels of Fst, an 
inhibitor of these molecules, may lead to muscle wasting 
(Zimmers et al., 2002; Costelli et al., 2008). With respect to 
the latter, the Fst288 isoform, which binds to the extracellu-
lar matrix and thus acts locally, is both necessary and sufficient 
for maintenance of normal muscle mass. This is demonstrated 
by the comparison between the wasted Fst+/ mouse and the 
normal muscle mass of mice expressing only the Fst288 iso-
form (Lee et al., 2010; Brown et al., 2011). Therefore, find-
ing that FAP+ cells of skeletal muscle not only produced this 
isoform but also were the only source of Fst biosynthesis in 
this tissue (Fig. 3, H and I) could explain how the loss of this 
cell led to a reduction in muscle mass. The stabilization of 
muscle mass and cessation of AcvRIIB signaling despite the 
continued decrease of FAP+ stromal cells and Fst is consistent 
with the compensatory lowering of Mstn expression seen by 
day 22 (Fig. 3 E). The decrease in Lama2 expression in the 
mice depleted of FAP+ stromal cells also could have con-
tributed to muscle atrophy, as the dy3K/dy3K mouse model of 
congenital muscular dystrophy with Lama2 deficiency exhib-
its skeletal muscle wasting secondary to elevated atrogin-1 
and MuRF1 and proteasome-mediated protein degradation 
(Carmignac et al., 2011).
A second acute abnormality in mice depleted of FAP+ stro-
mal cells was a hypocellular bone marrow, which represented 
decreased frequencies of pro-Es, MEPs, pro–Bs, and CLPs 
(Fig. 4, A and B). The explanation for these changes became 
apparent when FAP+ stromal cells from bone marrow were 
found to express Cxcl12 and KitL (Fig. 4, E, F, and H), char-
acteristics of the previously described CAR cell, conditional 
depletion of which resulted in a similar hematopoietic pheno-
type (Omatsu et al., 2010). Although the observed phenotypes 
are similar, there are subtle differences, such as the increase in 
multipotent progenitors seen with the depletion of FAP+ cells 
but not with the loss of Cxcl12-expressing cells. This finding 
may reflect the existence of FAP and Cxcl12-single express-
ing cells, as indicated by the occurrence of acute liver necrosis 
with the ablation of Cxcl12+ cells (Omatsu et al., 2010) but 
normal liver function tests in mice depleted of FAP+ cells 
(Table 1). FAP+ cells from the bone marrow also expressed 
Lepr, a marker of perivascular cells that produce KitL (Ding 
et al., 2012). The absence of an effect on HSCs in the DTX-
treated mice, however, may be accounted for by the incom-
plete ablation of FAP+ cells and the absence of FAP expression 
by endothelial cells, which are the second major source of 
KitL in the bone marrow (Ding et al., 2012). Furthermore, 
although FAP+ cells express Lepr, this does not exclude the 
presence of Lepr-expressing cells that are FAP, which would 
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RNA-Seq. Total RNA from the sorted cells was prepared using the PureLink 
RNA Mini kit from Invitrogen. The MessageAmp II aRNA kit (Ambion) 
was used for amplification of 100–500 ng total RNA according to the 
manufacturer’s instructions. The double-strand cDNA was subjected to 
library preparation using the Illumina mRNA sample preparation kit 
(Illumina) directly to the 3 adenylation step and according to manufacturer’s 
protocol. Sequence-by-synthesis single-end reads of 72-bp length using 
the SBS Sequencing kit (Illumina) were generated on the Genome Analyzer 
IIx (Illumina).
In vivo imaging. Mice were intraperitoneally injected with 150 µg/g 
body weight D-luciferin (PerkinElmer) and imaged using IVIS (Xenogen). 
Whole body images were acquired for 20 s at 1.5-cm stage height, and or-
gans were imaged for 20 s at 0.5-cm stage height. Data were analyzed using 
Living Image (PerkinElmer).
Flow cytometry. Single cell suspensions were made and stained as previ-
ously described (Kraman et al., 2010). Cell sorts were performed using the 
MoFlo system (Dako). Antibodies were obtained from eBioscience except 
CD4 H29.19 (BD), -hFAP AF3715 (R&D Systems), and the biotinylated 
mouse –sheep IgG GT-34 (Sigma-Aldrich).
Computational methods. RNA-Seq data were mapped to the iGenomes 
UCSC mm9 reference using the bowtie2 short read mapper (Langmead and 
Salzberg, 2012), and tophat2 was used to map junction reads. Cufflinks2 
(Trapnell et al., 2010) was used to calculate gene FPKM expression values 
with bias adjustment. RPKM values were calculated using count data from 
htseq-count version 0.5.3p4 in Python version 2.7. CD4+ T cell subset 
RNA-Seq data were obtained from the study by Wei et al. (2011; GEO 
series no. GSE20898). Expression levels for RPKM were then discretized 
into lowly expressed (LE) and highly expressed categories, as previously 
described (Hebenstreit et al., 2011). Genes with RPKM values that were 
LE were then filtered out of clustering and correlation calculations (which 
were calculated using Pearson’s r2 and Spearman’s ), whereas genes with no 
expression were filtered from FPKM correlations.
qRT-PCR analysis. mRNA was extracted using TRIzol (Invitrogen) and 
analyzed by quantitative real-time PCR using the SuperScript III Platinum 
One-Step qRT-PCR system (Invitrogen). Values for each gene were nor-
malized to the relative quantity of Tbp mRNA in each sample. Primers 
probes were obtained from Applied Biosystems.
ELISA. Protein was extracted as previously described (Omatsu et al., 2010). 
Concentrations of KitL and Cxcl12 were measured using Quantikine kits 
(R&D Systems) according to the manufacturer’s instructions.
Microscopy. Femurs were fixed overnight in 10% NBF and then decalcified 
in 10% EDTA for 21 d, changing the solution daily. The femurs were then 
cut in half and dehydrated in sucrose solution for 48 h before being moved 
through increasing concentrations of OCT before freezing in OCT. Slides 
were prepared and stained as previously described (Kraman et al., 2010). 
Antibodies used were Osteocalcin mOC(1–20) (Takara Bio Inc.), Osteopontin 
P-18 (Santa Cruz Biotechnology, Inc.), Lama2 4H8-2 (Enzo Life Sciences), 
and FAP AF3715 (R&D Systems).
Western blot. Protein was extracted as previously described (Costelli et al., 
2008). Protein was separated by NuPAGE (Invitrogen) transferred to nitro-
cellulose using the iBlot system (Invitrogen) and probed with antibodies 
against 1 µg/ml Fst (Santa Cruz Biotechnology, Inc.) and 1 µg/ml -actin 
(Abcam) before probing with IRDye secondary antibodies (LI-COR Bio-
sciences). Membranes were scanned and fluorescence was quantified using 
the Odyssey fluorescence imaging system (LI-COR Biosciences) according 
to the manufacturer’s instructions.
of the dystroglycan complex in cancer cachexia (Acharyya 
et al., 2005). Similarly, the hypoproliferative bone marrow 
of cancer patients with normocytic, normochromic anemia 
(Spivak, 2005) is compatible with the hematopoietic pheno-
type of cancer-bearing mice in which FAP+ cells are depleted 
from the bone marrow (Fig. 7 C). Collectively, these observa-
tions add to the increasing awareness of the capacity of tumors 
to affect distal sites, as has been reported for the development 
of the metastatic niche (Peinado et al., 2011), and emphasize 
that these alterations of the FAP+ stromal cell in normal tis-
sues are as important to consider as are the functions of the 
FAP+ cell in the tumor stroma.
However, the present study does not determine whether 
the cancer-induced loss of FAP-expressing stromal cells in 
normal tissues reflects cell death, as occurs in the DTX-treated 
BAC transgenic mice, migration to another site, perhaps con-
tributing to the accumulation of FAP+ stromal cells in the 
tumors, or development into a FAP-negative stromal cell that 
has lost a capacity for the production of tissue-specific pro-
teins, such as those required for the maintenance of skeletal 
muscle and bone marrow. Our study also has not identified 
what is produced by tumors to alter the tissue FAP+ stromal cell 
or whether the alteration is reversible after elimination of a 
cancer. Based on the finding of a persistent decrease of FAP+ 
stromal cells in skeletal muscle after DTX-mediated deple-
tion, the restoration of FAP+ stromal cells may be predicted 
to occur only if the tumor-induced loss reflects a reversible 
developmental process.
From the perspective of whether the killing of FAP+  
cells might be a viable therapeutic approach for overcoming 
tumoral immune suppression, this study indicates that a more 
nuanced strategy will be required. FAP+ stromal cells reside 
in many normal tissues, and in at least two of these they have 
essential functions, findings which preclude adopting this 
simplistic clinical strategy. The revelation of the complexity 
of the FAP+ stromal cell, however, is offset not only by the 
uncovering of a potentially new stromal cell lineage with 
roles in tissue homeostasis, but also by the unexpected dis-
covery that two paraneoplastic syndromes, cachexia and ane-
mia, may be caused by the idiopathic alteration of these stromal 
cells from skeletal muscle and bone marrow.
MATERIALS AND METHODS
BAC clone modification and purification. A 206-kb BAC clone (RP23-
16A15) containing the fap gene was purchased from BACPAC resources. The 
BAC was modified by introducing the reporter construct at the start ATG of 
the fap gene by homologous recombination. Undamaged BAC was purified 
using a CsCl gradient purification.
Mice. All experiments were performed under guidelines of and were 
approved by the UK Home Office and the animal ethics committee of the 
University of Cambridge. Transgenic mice were generated via pronuclear 
injection of BAC DNA into 0.5-d fertilized ova of F1(C57BL/6 × CBA) 
donors. Mice positive for the transgene were identified by PCR and back-
crossed at least 10 times to the C57BL/6 Tyr/ background. DTX was ad-
ministered in all experiments at a dose of 25 ng/g, and the C26 cells were 
subcutaneously inoculated into the flank of appropriate animals (2 × 106 cells 
per mouse).
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